Quavonlimab
Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody[1].
Product Specifications
CAS Number
[2254059-25-9]
Product Name Alternative
MK-1308
UNSPSC
12352203
Target
CTLA-4
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/quavonlimab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Quavonlimab]
Molecular Weight
(144.24 kDa)
References & Citations
[1]Perets R, et al. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021;32 (3) :395-403.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
LBN262a 12 Cases / 24 Cores
Bone tumor test tissue array with normal tissue as control, including TNM, clinical stage, 12 cases/24 cores, replacing T262
Ask
View Details 253264-Biotin 100 µL
UGT2B7 (UDP Glucuronosyltransferase 2 Family, Polypeptide B7, UGT2B9) (Biotin)
Ask
View Details 
